Hospira and healthcare IT firm Cerner are joining forces to develop the companies' infusion pump information platform, building on previous efforts to better integrate Hospira's infusion pumps with Cerner's electronic medical record systems.
Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.
In a strongly worded statement, the FDA told hospitals to stop using Hospira's Symbiq Infusion System because it can be remotely accessed by hackers, allowing the unauthorized user "to control the device and change the dosage the pump delivers, which could lead to over- or under-infusion of critical patient therapies." The agency's move marks another step to patrol the cybersecurity of medical devices, an issue that has long bedeviled Hospira's infusion pumps in particular.
After recalling 18 million vials last January of a painkiller commonly used in surgery, sterile injectables maker Hospira indicated that it was on top of the problem. But the company now says new manufacturing issues have cropped up that have led it to recall more than 20.7 million more vials of ketorolac, a drug on the FDA shortage list.
Pfizer intends a close one of its plants in India, a facility that has sat mostly idle for two years. But it is not as if Pfizer will be short on manufacturing capacity in the country. As soon as it completes its $15 billion deal to buy Hospira, it will get that company's massive manufacturing network there, including a brand-spanking-new plant in Vizag.
The first half of 2015 is over and done, and as companies prep their earnings releases, we're looking at a different sort of scorecard: the one filled out by investors. In the realm of stock performance, some big drugmakers delivered big gains over the first half of the year.
Hospira continues to forge a new market reality around biosimilars, capturing wide swathes of market share with deep discounts for its biosimilar of Merck's arthritis blockbuster Remicade. Hospira has reportedly captured a public contract in France by offering a price that amounts to a 45% savings.
After dealing with two preapproval inspections and two dozen FDA observations, injectables specialist Hospira says it has gotten FDA approval and is ramping up production at its new plant in India.
The game is on at Hospira's massive new manufacturing plant in India. After two delays to work out kinks identified by the FDA, the drugmaker says the agency has signed off on it and Hospira has started "limited commercial production at the facility."
Two months ago, the FDA issued a warning letter for a Hospira plant in Italy noting a number of problems including its lack of controls for access to prevent data deletions from test equipment. Health Canada has decided that issue is enough for it to ban products coming out of the sterile manufacturing facility.